Page last updated: 2024-10-30

lg 100268 and Alzheimer Disease

lg 100268 has been researched along with Alzheimer Disease in 1 studies

LG 100268: a retinoid X receptor (RXR) selective compound; structure given in first source

Alzheimer Disease: A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)

Research Excerpts

ExcerptRelevanceReference
"Previous data demonstrate that bexarotene (Bex), retinoid X receptor (RXR) agonist, reduces soluble and insoluble amyloid-β (Aβ) in Alzheimer disease (AD)-transgenic mice either by increasing the levels of mouse apolipoprotein E (apoE) or increasing ABCA1/ABCG1-induced apoE lipoprotein association/lipidation."3.80Amyloid-β pathology and APOE genotype modulate retinoid X receptor agonist activity in vivo. ( Ben Aissa, M; Collins, NC; Koster, KP; LaDu, MJ; Lee, SH; Luo, J; Tai, LM; Thatcher, GRJ; Wang, YT, 2014)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Tai, LM1
Koster, KP1
Luo, J1
Lee, SH1
Wang, YT1
Collins, NC1
Ben Aissa, M1
Thatcher, GRJ1
LaDu, MJ1

Other Studies

1 other study available for lg 100268 and Alzheimer Disease

ArticleYear
Amyloid-β pathology and APOE genotype modulate retinoid X receptor agonist activity in vivo.
    The Journal of biological chemistry, 2014, Oct-31, Volume: 289, Issue:44

    Topics: Administration, Oral; Alzheimer Disease; Amyloid beta-Peptides; Animals; Apolipoproteins E; ATP Bind

2014